Get the Stockscreener App
13.38
2.92%
0.38
After Hours:
13.63
0.25
+1.87%
Maze Therapeutics Inc stock is traded at $13.38, with a volume of 312.53K.
It is up +2.92% in the last 24 hours and up +0.00% over the past month.
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
See More
Previous Close:
$13.00
Open:
$12.56
24h Volume:
312.53K
Relative Volume:
7.37
Market Cap:
$597.56M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$12.56
$14.32
1-Week Range:
$11.34
$16.09
52-Week Range:
$11.34
$16.09
Maze Therapeutics Inc Stock (MAZE) Company Profile
Compare MAZE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
13.38 | 597.56M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.23 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Maze Therapeutics Inc Stock (MAZE) Latest News
Maze Therapeutics begins Phase 2 trial for kidney disease drug By Investing.com - Investing.com Nigeria
Maze Therapeutics begins Phase 2 trial for kidney disease drug - Investing.com India
Maze Therapeutics Doses First Patient in Phase 2 HORIZON - GlobeNewswire
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease - GlobeNewswire Inc.
Maze Therapeutics stock hugs flat line following $140M IPO - MSN
Maze Therapeutics valued at $690.4 million in lukewarm Nasdaq debut - MSN
Finance Watch: Metsera, Maze Go Public, Bringing 2025 US IPO Total To Three - News & Insights
Metsera and Maze Therapeutics Secure $415M in IPOs, Signaling Strong Start for US Health Care Industry - Hoodline
Maze Therapeutics IPO opens trading modestly higher - MSN
Maze Therapeutics valued at $690.4 million as shares rise marginally in market debut - MSN
Biotech firm Maze Therapeutics raises $140 million in US IPO - MSN
Maze Therapeutics IPO opens trading modestly higher By Investing.com - Investing.com Canada
4 Firms Guide Pair Of Biotech IPOs Raising $415M Combined - Law360
Maze Therapeutics Opens At $16.12, IPO Priced At $16 By Investing.com - Investing.com Canada
Metsera and Maze IPOs look to bring $415M to Nasdaq - BioWorld Online
FiDi-based obesity drug maker sees $1.9B IPO - Crain's New York Business
Two more biotechs, Metsera and Maze, cross IPO finish line - pharmaphorum
Maze Therapeutics Prices Upsized IPO at $16 Per Share -January 31, 2025 at 04:39 am EST - Marketscreener.com
Metsera and Maze Therapeutics Boost US Health Care IPOs to Record LevelsNews and Statistics - IndexBox, Inc.
Metsera, Maze secure combined $415 million in IPOs - BioPharma Dive
Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs - Yahoo Finance
MAZEMaze Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Maze Therapeutics Prices Upsized IPO at $16, Raising $140M for Precision Medicine - StockTitan
Maze Therapeutics Announces Pricing of Upsized Initial Public Offering - GlobeNewswire
Maze Therapeutics Inc. (MAZE): Kidney Disease Biotech IPO Garnering Attention from Sector Investors - Smartkarma
Three biotechs go public as IPO momentum increases - The Pharma Letter
Pompe Disease Pipeline 2024: Mechanism of Action, Route of Administration, and Clinical Trial Insights Explored by DelveInsight | M6P Therapeutics, Entrada Therapeutics, Maze Therapeutics, Astellas - The Globe and Mail
Obesity-Focused Metsera Leads Biotech Firms Eyeing IPOs - Law360
Drug developer Maze Therapeutics eyes up to $728 million valuation in US IPO - MSN
Maze Therapeutics Inc. (MAZE): Kidney Biotech with Blockbuster Potential Sets Terms for IPO - Smartkarma
Maze Therapeutics targets up to $728 million valuation in US IPO - MSN
Maze Therapeutics Files for 7.8M Share IPO at $15-$17/sh - Investing.com Canada
Maze Therapeutics Inc. (MAZE): Phase 2 Biopharma Targeting Kidney Disease Files for IPO. - Smartkarma
The Friday Biotech Perspective #36 - substack.com
Maze Therapeutics Seeks IPO For Trials Ramp-Up (Pending:MAZE) - Seeking Alpha
Metsera, Maze will play canary in the IPO coal mine - BioCentury
Kidney disease drugmaker Maze files for IPO - BioPharma Dive
Peninsula company angles to be Bay Area's first biotech IPO of 2025 - The Business Journals
Maze Therapeutics raises $115m to advance kidney disease candidates - Pharmaceutical Technology
Maze Therapeutics Announces Oversubscribed $115 Million Financing to Support Advancement of Clinical-Stage Programs and Future Pipeline - Business Wire
Maze Therapeutics Reports Positive First-in-Human Data From Phase 1 Healthy Volunteer Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease (AKD) - BioSpace
Maze Therapeutics to Present New Data Supporting Advancement of MZE829 and MZE782 Clinical Development at American Society of Nephrology’s Kidney Week and American Society of Human Genetics Annual Meeting - Business Wire
Maze Therapeutics Initiates Phase 1 First-in-Human Trial Evaluating MZE782 as a Potential Treatment for Chronic Kidney Disease - Business Wire
Navigating the IPR maze: India's pharmaceutical challenge - Express Pharma
Maze Therapeutics - The Pharma Letter
Regulators caused breakup of potential $750 million drug deal — now they've blessed company's latest move - The Business Journals
Maze Therapeutics discovers new SLC6A19 inhibitors - BioWorld Online
New SLC6A19 inhibitors divulged in Jnana Therapeutics patents - BioWorld Online
Maze Therapeutics presents new APOL1 inhibitors - BioWorld Online
Maze Therapeutics to Participate in Upcoming Investor Conferences - Business Wire
Antitrust M&A Snapshot | Q4 2023 - McDermott Will & Emery
Maze Therapeutics Inc Stock (MAZE) Financials Data
There is no financial data for Maze Therapeutics Inc (MAZE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):